Genzyme Strengthens Its Gene Therapy Program
News Jan 12, 2006
Genzyme has announced that it has strengthened and diversified its ability to develop gene therapy products that use either adenovirus or adeno-associated virus vectors.
In December, the company bought extensive gene therapy assets from US company Avigen for $12m (€10 m), including patents focusing on adeno-associated virus technology; a phase I/II clinical development program in Parkinson's disease; and a clinical collaboration in haemophilia.
In November, Genzyme also paid $3.2 m to acquire the viral manufacturing facilities from US company Cell Genesys.
Genzyme plans to use the acquired assets and the facilities to support its existing gene therapy research and clinical trials, and to broaden its manufacturing capabilities in both adenovirus and adeno-associated virus vectors, which are used to deliver genes to the appropriate cells in patients.
"We also look forward to advancing Avigen's ongoing work in Parkinson's disease and haemophilia, areas where we believe gene therapy could play a meaningful role in treatment," said Rich Gregory, Genzyme's head of research.
In the wake of a number of large-scale investments in biological drugs production capacity, from the likes of Genentech, GlaxoSmithKline and Bristol-Myers Squibb, the company opened four new European facilities in September as part of an investment package expected to cost $540m.
4000-Year Old DNA Helps Track the Spread of Rice Farming in AsiaNews
Rice farming spread far and wide in ancient Southeast Asia, but how it got there has been a mystery. Now, a study of 4000-year-old DNA—a rare find in this region—suggests it came with farmers migrating from China, where rice farming originated.
Island Life: Worm-eating Mice Hold Clues to EvolutionNews
How much space does a population need to branch out and form a new species? A small island in the Philippines, and four species of mice that live on it, have helped researchers work out the answer.READ MORE
Gonorrhoea Genome Maps Out STD Across EuropeNews
The first European-wide genomic survey of gonorrhoea has mapped antibiotic resistance in this sexually transmitted disease throughout the continent. Researchers also showed that using DNA sequencing data they could accurately determine antibiotic resistance and identify incorrect laboratory test results.
Comments | 0 ADD COMMENT
Epigenetics in the nervous system: development and disease
Oct 01 - Oct 03, 2018